Program
efimosfermin alfa
Also written as “Efimosfermin alfa”, “Efimosfermin” and “Efimosfermin Alfa”.
In GlaxoSmithKline’s pipeline, Fibroblast growth factor 21 (FGF21) analog
. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases, Alcoholic · Obesity, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 97 open or running | phase 3since Oct 15, 2025 | May 5, 2021 | Oct 13, 2027phase 1 · NCT07358546 |
| Novartis | 10 open or running | phase 1since Feb 9, 2018 | Feb 9, 2018 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
efimosfermin alfa GSK6519754
, phase 3, as of Sep 30, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- AcquisitionGSK acquired Boston Pharmaceuticals, and with it efimosfermin, with the milestones and royalties owed to Novartis.Completed Jul 7, 2025 · Source: GSK, Jul 7, 2025
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 9, 2018First study: phase 1 study in ObesityFirst studyNCT03466203 · 61 enrolled · United States
- Feb 29, 2024Named efimosfermin alfaINNProposed as its International Nonproprietary Name in WHO's List 130 · before, LLF580
- Jul 7, 2025GSK acquired Boston PharmaceuticalsAcquisitionWith it efimosfermin, with the milestones and royalties owed to Novartis · completed · GSK
TargetBeta
“Fibroblast growth factor 21 (FGF21) analog”the company's pipeline, read by Claude · source
Other programs on FGF21
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pegozafermin | 89bio-inc | phase 3 | 8 |
| efruxifermin | Novo Nordisk | phase 3 | 6 |
| zalfermin | Novo Nordisk | phase 2 | 10 |
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03466203Obesity · United States | 1 | Completed | Nov 13, 2019 | 61 |
How it is read
Names in the registry
- “Efimosfermin alfa”, 7 entries
- “Efimosfermin”, 2 entries
- “Efimosfermin Alfa”, 1 entry
- “LLF580”, 1 entry
Codes read as this program: BOS580.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 6 studies
- Fatty Liver, 2 studies
- Liver Diseases, Alcoholic, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.